搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
来自MSN
2 天
Daily Oral Edaravone for ALS No Better Than On/Off Regimen
Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...
News Medical on MSN
6 天
Edaravone shows promise in targeting brain tumor stem cells
Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.
6 天
on MSN
Repurposing drugs to eliminate cellular origins of brain tumors
Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy ...
Medindia
3 天
Amyotrophic Lateral Sclerosis Drug May Help Battle Against Incurable Glioblastoma
A promising ALS drug may help combat glioblastoma by targeting the cancerous stem cells that fuel tumor growth.
Medscape
2 天
ALS Update: Drug Therapy Continues to Offer Little Benefit
Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...
生物通
4 天
旧药新用:ALS药物Edaravone可靶向脑肿瘤干细胞 有望治疗胶质母细胞瘤
胶质母细胞瘤是侵袭性脑肿瘤,中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号,而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此,加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生,并延长临床前模型的寿命 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈